COVID-19 Vaccine

Development of a COVID-19 vaccine that can be distributed at room temperature has a significant impact on global health and would address an emergent, unmet need.
Covid 19 Header ImageCovid 19 Header Image
Engimata is developing a COVID-19 vaccine candidate. This COVID-19 vaccine is made of our proprietary  lipid nanoparticles (L-Vac) and recombinant viral protein subunits from coronavirus SARS-CoV-2. 
Covid-19 vaccine particleCovid-19 vaccine particle
​​​​​​​Figure above illustrates a COVID-19 vaccine particle consisting of a liposome and recombinant viral protein antigens from SARS-CoV-2. We have developed different vaccine development processes and shown promising results in animal studies. Our COVID-19 vaccine is currently in the preclinical stage.

Preliminary results have shown that Engimata’s freeze-dried COVID-19 vaccine candidate is stable at 25C at least for 3 months and can be distributed without the need for a cold or ultra-cold supply chain. ​​​​Engimata’s lyophilized COVID-19 vaccine can be easily reconstituted prior to injection.
Covid Vaccine ContainerCovid Vaccine Container
Man with covid vaccine containerMan with covid vaccine container